SCHEMBL2011849

SCHEMBL2011849

CC(=O)Oc1cc(OCc2ccccc2)cc(OC(C)=O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
MAOB P27338 4/20 0.58
ALDH1A1 P00352 2/20 0.55
NR4A2 P43354 2/20 0.53
NR4A1 P22736 1/20 0.53
NR4A3 Q92570 1/20 0.53
SRD5A2 P31213 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
PTPN1 P18031 1/20 0.52
PTGS1 P23219 2/20 0.51
PTGS2 P35354 2/20 0.51
ALOX5 P09917 2/20 0.51
BACE1 P56817 1/20 0.50
PARP10 Q53GL7 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
SLC6A2 P23975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8896850 0.94 MEN1 (0.58) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL6195527 0.94 MAOB (0.59) MEN1KMT2AMAOBALDH1A1SRD5A2
SCHEMBL2572210 0.92 MEN1 (0.79) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL8209102 0.92 MEN1 (0.56) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL27684205 0.92 MEN1 (0.56) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL5746820 0.90 MAOB (0.68) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL1068959 0.88 MAOB (0.70) MAOBALDH1A1NR4A2NR4A1NR4A3
SCHEMBL8216288 0.87 MEN1 (0.51) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL8896523 0.86 MEN1 (0.50) MEN1KMT2AMAOBALDH1A1NR4A2
SCHEMBL6588551 0.86 MEN1 (0.53) MEN1KMT2AMAOBALDH1A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 MEN1 4472/4885KMT2A 4561/4885MAOB 1394/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 MEN1 4472/4885KMT2A 4561/4885MAOB 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.